Premium
Comparison between self‐reported nutrient intake from 24‐h recall and Food Frequency Questionnaire (FFQ), at baseline, among Spanish overweight and obese participants in a metabolic trial
Author(s) -
Soto-Méndez María-José,
Martìnez-de-Victoria Emilio,
Lobo Gabriela,
Boza Julio,
Kellerhals Michelle,
Pérez-de-la-Cruz Antonio,
Gil Angel,
Mesa Maria-Dolores,
Aguilera Concepción-María
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.813.6
Subject(s) - medicine , overweight , food frequency questionnaire , crossover study , placebo , randomized controlled trial , obesity , demography , environmental health , alternative medicine , pathology , sociology
Background Dietary intake during metabolic trials has been controlled using one or another assessment method. The luxury of comparison of mutual results is rarely available. Objective To compare data between self‐reported nutrient intake from 24‐h recall and FFQ at baseline among overweight and obese Spanish participants in a metabolic trial. Methods 151 volunteers (age 18–65 y) were enrolled in a randomized, placebo‐controlled, double‐blind, crossover trial. Subjects were interviewed by 2 standardized nutritionists in a baseline 24‐h recall and a FFQ. Results At a group level, median FFQ‐derived energy was estimated as higher than that with 24h‐recall (2600 vs 1874 kcal) as were carbohydrates (273 vs 206 g), proteins (117 vs 87 g) and fats (116 vs 81 g), respectively. All differences were significant at p<0.05. At the individual level, 83% of subjects reported more energy on FFQ and 17% more on 24‐h recall interviews. Regarding macronutrients, 77% of subjects for carbohydrates, 81% for protein and 84% for fat reported greater intakes with the FFQ approach. Conclusion As expected, results from this study indicate that FFQ overestimated dietary intake in comparison to the 24‐h recall. This trial is registered at clinicaltrials.gov as NCT01290250 and it is funded by The Coca‐Cola Company .